Cogent Biosciences, Inc. (COGT)

Market Cap	784.90M
Revenue (ttm)	n/a
Net Income (ttm)	-125.54M
Shares Out	69.58M
EPS (ttm)	-2.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	619,319
Open	11.2
Previous Close	11.23
Day's Range	11 - 11.47
52-Week Range	3.79 - 18.07
Beta	-0.71
Analysts	Buy
Price Target	21.59 (+94.5%)
Earnings Date	Nov 16, 2022

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly...

• Industry: Biotechnology
• IPO Date: Mar 29, 2018
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: COGT

Analyst Forecast

According to 12 analysts, the average rating for COGT stock is "Buy." The 12-month stock price forecast is 21.59, which is an increase of 94.50% from the latest price.

Price Target

$21.59

(94.50% upside)

Analyst Consensus: Buy